A new host for the manufacture of challenging drug targets

用于制造具有挑战性的药物靶标的新宿主

• 批准号: 10054371
• 金额: --
• 依托单位: BCL2020 LTD
• 依托单位国家: 英国
• 项目类别: Investment Accelerator
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10054371
• 关键词: new; host; manufacture; challenging; drug

As research into topics such as cancer, malaria and parasitic diseases advances and expands into drug discovery and treatment programmes, access to the tools needed to ensure successful outcomes become increasingly important. A limiting factor in the development of therapeutics is a lack of recombinant proteins for candidate drug activity assays or for mechanistic/structural studies. Research Use Only (RUO) proteins are key reagents, yet availability is often unreliable, with existing production methods either unable to generate the molecules at all, or at extremely high prices.BCL's novel Clostridial expression system has the ability to express proteins previously unobtainable in any existing expression system. This project seeks to develop and optimise this system to increase yields and tackle some of the hardest to express proteins in the field.

随着对癌症、疟疾和寄生虫病等专题的研究取得进展并扩展到药物发现和治疗方案，获得确保成功结果所需的工具变得越来越重要。治疗剂开发中的限制因素是缺乏用于候选药物活性测定或用于机制/结构研究的重组蛋白。研究专用（RUO）蛋白质是关键试剂，但可用性往往不可靠，现有的生产方法要么根本无法产生分子，要么价格极高。BCL的新型梭菌表达系统能够表达以前任何现有表达系统都无法获得的蛋白质。该项目旨在开发和优化该系统，以提高产量并解决该领域中一些最难表达的蛋白质。